We examined whether reductions in body fat stores and insulin resistance in Syrian hamsters induced by bromocriptine are associated with reductions in daily norepinephrine (NE) and serotonin activities as indicated by their extracellular metabolite levels in the ventromedial hypothalamus (VMH). High levels of these monoamines within the VMH have been suspected to induce obesity and insulin resistance. Microdialysate samples from the VMH of freely moving obese male hamsters (BW: 208 ± 5 g) were collected hourly over a 25-hour period before bromocriptine treatment, during the first day of and after 2 weeks of bromocriptine treatment (800 µg/animal daily, i.p.), and body composition and glucose tolerance analyses were conducted before and after 2 weeks of treatments. The microdialysate samples were analyzed by HPLC for metabolites of serotonin: 5-hydroxy-indoleacetic acid (5-HIAA), NE: 3-methoxy-4-hydroxy-phenylglycol (MHPG), and dopamine: homovanillic acid (HVA). Bromocriptine treatment for 14 days significantly reduced body fat by 60% and areas under the glucose and insulin curves during a glucose tolerance test by 50 and 46%, respectively. Concurrently, extracellular VMH contents of 5-HIAA, MHPG, and HVA were reduced by 50, 29 and 66%, respectively (p < 0.05). Similarly, VMH 5-HIAA and MHPG contents were 48 and 44% less, respectively (p < 0.05), in naturally glucose-tolerant hamsters compared with naturally glucose-intolerant hamsters. Bromocriptine induced reductions of body fat, and improvements in glucose intolerance may result in part from its ability to decrease serotonin and NE activities in the VMH.

Keywords:
Glucose, Ventromedial hypothalamus, Obesity, Bromocriptine, Catecholamines, Serotonin, Hamster
1.
Frohman LA: Hypothalamic control of metabolism; in Morgane PJ, Panksepp J (eds): Handbook of the Hypothalamus, New York, Marcel Dekker, vol 2: Physiology of the Hypothalamus, 1980, pp 519–555.
2.
Luiten PGM, Ter Horst GJ, Steffens AB: The hypothalamus, intrinsic connections and outflow pathways to the endocrine system in relation to the control of feeding and metabolism. Prog Neurobiol 1987;28:1–54.
3.
Jansen ASP, Nguyen XV, Karpitskiy V, Metenleiter TC, Loewy AD: Central command neurons of the sympathetic nervous system: Basis of the fight-or-flight response. Science 1995;270:644–646.
4.
Benzo CA: The hypothalamus and blood glucose regulation. Life Sci 1983;32:2509–2515.
5.
Borg WP, Sherwin RS, During MJ, Borg MA, Shulman GI: Local ventromedial hypothalamus glucopenia triggers counterregulatory hormone release. Diabetes 1995;44:180–184.
6.
Borg MA, Sherwin RS, Borg WP, Tamborlane WV, Shulman GI: Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997;99:361–365.
7.
Shimazu T, Ishikawa K: Modulation by the hypothalamus of glucagon and insulin secretion in rabbits: Studies with electrical and chemical stimulations. Endocrinology 1981;108:605–611.
8.
Takagashi A, Shimazu T: Hypothalamic regulation of lipid metabolism in the rat: Effect of hypothalamic stimulation on lipolysis. J Auton Nerv Syst 1981;4:195–205.
9.
Takahashi A, Ishimaru H, Ikarashi Y, Kishi E, Maruyama Y: Effects of ventromedial hypothalamus stimulation on glycogenolysis in rat liver using in vivo microdialysis. Metabolism 1997;46:897–901.
10.
Chaouloff F, Baudric V, Laude D: Evidence that the 5-HT1A receptor agonists buspirone and ipsapirone activate adrenaline release in the conscious rat. Eur J Pharmacol 1990;177:107–110.
11.
Nonogaki K, Iguchi A: Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci 1997;60:797–807.
12.
Suzuki M, Matsuda T, Asano S, Somboonthum P, Takuma K, Baba A: Increase of noradrenaline release in the hypothalamus of freely moving rat by postsynaptic 5-hydroxytryptamine1A receptor activation. Br J Pharmacol 1995;115:703–711.
13.
Lin MT, Shian LR: Stimulation of 5-hydroxytryptamine nerve cells in dorsal and median raphe nuclei elevates glucose in rats. Pflügers Arch 1991;417:441–445.
14.
Reaven GM: Role of insulin resistance in human disease. Diabetes 1988;37:1595–1607.
15.
Salkovic M, Lackovic Z: Central nervous system in diabetes. Diabetes Croat 1987;16:5–17.
16.
Cincotta AH, Schiller BC, Meier AH: Bromocriptine inhibits the seasonally occurring obesity, hyperinsulinemia, insulin resistance and impaired glucose tolerant in the Syrian hamster, Mesocricetus auratus. Metabolism 1991;40:639–644.
17.
Cincotta AH, MacEachern TA, Meier AH: Bromocriptine redirects metabolism and prevents seasonal onset of obese hyperinsulinemic state in Syrian hamsters. Am J Physiol 1993;264:E285–E293.
18.
Cincotta AH, Meier AH: Bromocriptine inhibits in vivo free fatty acid oxidation and hepatic glucose output in seasonally obese hamsters, Mesocricetus auratus. Metabolism 1995;44:1349–1355.
19.
Glass JD, Randolph WW, Ferreira SA, Rea MA, Hauser UE, Blank JL, De Vries MJ: Diurnal variation in 5-hydroxyindoleacetic acid output in the suprachiasmatic region of the Siberian hamster assessed by in vivo microdialysis: Evidence for nocturnal activation of serotonin release. Neuroendocrinology 1992;56:582–590.
20.
Kalen P, Strecker RE, Rosengren E, Bjorklund A: Endogenous release of neuronal serotonin and 5-hydroxyindoleacetic acid in the caudate-putamen of the rat as revealed by intracerebral dialysis coupled to high-performance liquid chromatography with fluorimetric detection. J Neurochem 1988;51:1422–1435.
21.
Wolf WA, Youdim MBH, Kuhn DM: Does brain 5-HIAA indicate serotonin release or monoamine oxidase activity? Eur J Pharmacol 1985;109:381–387.
22.
Hernandez L, Lee F, Hoeboe B: Simultaneous microdialysis and amphetamine infusion in the nucleus accumbens and striatum of freely moving rats: Increase in extracellular dopamine and serotonin. Brain Res Bull 1987;19:623–628.
23.
Matos FF, Rollema H, Basbaum A: Characterization of monoamine release in the lateral hypothalamus of awake, freely-moving rats using in vivo microdialysis. Brain Res 1990;528:39–47.
24.
Green AR, Graham-Smith DG: The effect of drugs on the process regulating the functional activity of brain 5-hydroxytryptamine. Nature 1976;260:487–491.
25.
Ramirez AD, Ramirez VD, Meyer DC: The nature and magnitude of in vivo 5-hydroxyindoleacetic acid output from 5-hydroxytryptamine terminals is related to specific regions of the suprachiasmatic nucleus. Neuroendocrinology 1987;46:430–438.
26.
Shannon NJ, Gunnet JW, Moore KE: A comparison of biochemical indices of 5-hydroxy tryptaminergic neuronal activity following electrical stimulation of the dorsal raphe nucleus. J Neurochem 1986;47:958–965.
27.
Knigge KM, Joseph SA (eds): A Stereotaxic Atlas of the Brain of the Golden Hamster (Mesocricetus auratus), University of Cincinnati, Cincinnati, 1963.
28.
Hsiao JK, Ball BA, Morrison PF, Mefford IN, Bungay PM: Effects of different semipermeable membranes on in vitro and in vivo performance of microdialysis probes. J Neurochem 1990;54:1449–1452.
29.
De Souza CJ, Meier AH: Circadian and seasonal variations of plasma insulin and cortisol concentrations in the Syrian hamster, Mesocricetus auratus. Chronobiol Int 1987;4:141–151.
30.
Sheng HP, Huggins RA: A review of body composition studies with emphasis on total body water and fat. Am J Clin Nutr 1979;32:630–647.
31.
Wong WW, Lee LS, Klein PD: Deuterium and oxygen-18 measurements on microliter samples of urine, plasma, saliva, and human milk. Am J Clin Nutr 1987;45:905–913.
32.
Shimazu T: Central nervous system regulation of liver and adipose tissue metabolism. Diabetologia 1981;20:343–356.
33.
Luo S, Luo J, Hodge S: Chronic infusion of norepinephrine and serotonin into the ventromedial hypothalamus induces glucose intolerance and insulin resistance in hamsters (abstract). Diabetes 1997;46(suppl 1):84A.
34.
Shimazu T, Fukuda A, Ban T: Reciprocal influences of the ventromedial and lateral hypothalamic nuclei on blood glucose level and liver glycogen content. Nature 1966;210:1178–1179.
35.
Steffens AB, Damsma G, vander Gugten J, Luiten PGM: Circulating free fatty acids, insulin and glucose during chemical stimulation of hypothalamus in rats. Am J Physiol 1984;247:E765–E771.
36.
De Jong A, Strubbe JH, Steffens AB: Hypothalamic influence on insulin and glucagon release in the rat. Am J Physiol 1977;233:E380–E388.
37.
Bagdy G, Calogero AE, Murphy DL, Szemeredi K: Serotonin agonists cause parallel activation of the sympathalamo-pituitary-adrenocortical axis in conscious rats. Endocrinology 1989;125:2664–2669.
38.
Clement HW, Gemsa D, Wesemann W: Serotonin-norepinephrine interactions: A voltametric study on the effect of serotonin receptor stimulation followed in the N. raphe dorsalis and the locus coeruleus of the rat. J Neural Transm 1992;88:11–23.
39.
Fuller RW: Neurochemical effects of serotonin neurotoxins, an introduction. Ann NY Acad Sci 1978;305:178–181.
40.
Baudric V, Chaouloff F: Mechanisms involved in the hyperglycemic effect of the 5-HT1c/rHT2 receptor agonist, DOI. Eur J Pharmacol 1992;213:41–46.
41.
Chaouloff F, Laude D, Baudric V: Effects of the 5-HT1C/5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. Eur J Pharmacol 1990;187:435–443.
42.
Done CJG, Sharp T: Biochemical evidence for the regulation of central noradrenergic activity by 5-HT1A and 5-HT2 receptors: Microdialysis studies in the awake and anaesthetized rat. Neuropharmacology 1994;33:411–421.
43.
Freund P, Wolff HP, Kuhnle HF: (–)-BM 13.0913: A new oral antidiabetic agent that improves insulin sensitivity in animal models of type II (non-insulin-dependent) diabetes mellitus. Metabolism 1995;44:570–576.
44.
Shimazu T, Noma M, Saito M: Chronic infusion of norepinephrine into the ventromedial hypothalamus induces obesity in rats. Brain Res 1986;369:215–223.
45.
Muntzel MS, Anderson EA, Johnson AK, Mark AL: Mechanisms of insulin action on sympathetic nerve activity. Clin Exp Hypertens 1995;17:39–50.
46.
Rowe JW, Young JB, Minaker KL, Stevens AL, Pallotta J, Landsberg L: Effect of insulin and glucose infusions on sympathetic nervous system activity in normal man. Diabetes 1981;30:219–225.
47.
Fernstrom JD, Wurtman RJ: Elevation of plasma tryptophan by insulin in the rat. Metabolism 1972;21:337–342.
48.
Fernstrom JD, Wurtman RJ: Brain serotonin content: Physiological dependence on plasma tryptophan levels. Science 1971;173:149–152.
49.
Mackenzie RG, Trulson ME: Effects of insulin and streptozotocin-induced diabetes on brain tryptophan and serotonin metabolism in rats. J Neurochem 1978;30:205–211.
50.
Crandall EA, Fernstrom JD: Acute changes in brain tryptophan and serotonin after carbohydrate or protein ingestion by diabetic rats. Diabetes 1980;29:460–466.
51.
Fernstrom JD, Wurtman RJ: Brain serotonin content: Physiological regulation by plasma neutral amino acids. Science 1972;178:414–416.
52.
Chu PC, Lin MT, Shian LR, Leu SY: Alterations in physiologic functions and in brain monoamine content in streptozotocin-diabetic rats. Diabetes 1986;35:481–485.
53.
Crandall EA, Gills MA, Fernstrom JD: Reduction in brain serotonin synthesis rate in streptozotocin-diabetic rats. Endocrinology 1981;109:310–312.
54.
Trulson ME, Himmel CD: Decreased brain dopamine synthesis rate and increased (3H)sproperidol binding in streptozotocin-diabetic rats. J Neurochem 1983;40:1456–1459.
55.
Dourish CT: 5-HT receptor subtypes and feeding behaviour; in Bradley PB, Handley SL, Cooper SJ, Key BJ, Barnes NM, Coote JH (eds): Serotonin, CNS Receptors and Brain Function. Oxford, Pergamon Press, 1992, pp 179–202.
56.
Hutson PH, Donoboe TP, Curzon G: Infusion of the 5-hydroxytryptamine agonists RU24969 and TFMPP into the paraventricular nucleus of the hypothalamus causes hypophagia. Psychopharmacology 1988;95:550–552.
57.
Dryden S, Frankish SH, Wang Q, Williams G: Neuropeptide Y and energy balance: One way ahead for the treatment of obesity? Eur J Clin Invest 1994;24:293–308.
58.
Curzon G: Effect of tryptophan and of 5-hydroxytryptamine receptor subtype agonists on feeding; in Schwartz R (ed): Kynurenine and Serotonin Pathways. New York, Plenum Press, 1991, pp 377–388.
59.
Goldstein M, Lieberman A, Calne DB, Thorner MO (eds): Ergot compounds and brain function: Neuroendocrine and neuropsychiatric aspects. Advances in Biochemical Psychopharmacology, Raven Press, New York, 1980, vol 23.
60.
Carey RM, Van Loun GR, Baines AD, Kaiser DL: Suppression of basal and stimulated noradrenergic activities by the dopamine agonist bromocriptine in man. J Clin Endocrinol Metab 1983;56:595–602.
61.
Ziegler MG, Lake CR, Williams AC, Teychenne PF, Shoulson I, Steinsland O: Bromocriptine inhibits norepinephrine release. Clin Pharmacol Ther 1979;25:137–142.
62.
Jackson DM, Mohell N, Georgiev J, Bengtsson A, Larsson L, Magnusson O, Ross SB: Time course of bromocriptine induced excitation in the rat: Behavioural and biochemical studies. Naunyn-Schmiedeberg’s Arch Pharmacol 1995;351:146–155.
63.
Steinsland OS, Hieble JP: Dopaminergic inhibition of adrenergic neurotransmission as a model for studies on dopamine receptor mechanisms. Science 1978;199:443–445.
64.
Ferre S, Cortes R, Artigas F: Dopaminergic regulation of the serotonergic raphe-striatal pathway: Microdialysis studies in freely moving rats. J Neurosci 1994;14:4839–4846.
65.
Corrodi H, Fuxe L, Hoekfelt T, Lidbrink P, Ungerstedt U: Effects of ergot drugs on central catecholamine neurons: Evidence for a stimulation of central dopamine neurons. J Pharm Pharmacol 1973;25:409–412.
66.
Snider SR, Hutt C, Stein B, Prasad ALN, Fahn S: Correlation of behavioral inhibition or excitation produced by bromocriptine with changes in brain catecholamine turnover. J Pharm Pharmacol 1976;28:563–566.
67.
Markstein R, Herrling PL: The effect of bromocriptine on rat striatal adenylate cyclase and rat brain monoamine metabolism. J Neurochem 1978;31:1163–1172.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.